ROBERT W. WILKINS, M.D., F.A.C.P.
Since 1950 a number of new antihypertensive drugs have come into use and have helped to change not only our clinical management but also our basic concepts of essential hypertension. These drugs have in common only their antihypertensive property, and even this is mediated differently by each of them. Thus the ganglionic blocking drugs reduce the activity of the sympathetic nervous system, the veratrum products stimulate the depressor activity of the parasympathetic nervous system, the Rauwolfia derivatives lessen the pressor effects of central nervous agitation, hydralazine dilates the arteriolar system, particularly in the kidney, and chlorothiazide augments natruresis, and
WILKINS RW. NEW DRUGS FOR THE TREATMENT OF HYPERTENSION1. Ann Intern Med. ;50:1–10. doi: 10.7326/0003-4819-50-1-1
Download citation file:
Published: Ann Intern Med. 1959;50(1):1-10.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use